IP Verse

Therapeutic Combinations Of A Btk Inhibitor, A Pi3K Inhibitor, A Jak-2 Inhibitor, And/Or A Bcl-2 Inhibitor - EP3179991

The patent EP3179991 was granted to Acerta Pharma on Oct 6, 2021. The application was originally filed on Aug 11, 2015 under application number EP15757002A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3179991

ACERTA PHARMA
Application Number
EP15757002A
Filing Date
Aug 11, 2015
Status
Granted And Under Opposition
Sep 3, 2021
Grant Date
Oct 6, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STADA ARZNEIMITTELJul 5, 2022HAMM & WITTKOPPADMISSIBLE

Patent Citations (181) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2006167070
DESCRIPTIONUS2007135461
DESCRIPTIONUS2007135477
DESCRIPTIONUS2007142368
DESCRIPTIONUS2008139561
DESCRIPTIONUS2008200485
DESCRIPTIONUS2008269490
DESCRIPTIONUS2008287475
DESCRIPTIONUS2008312258
DESCRIPTIONUS2008312259
DESCRIPTIONUS2009029992
DESCRIPTIONUS2009233903
DESCRIPTIONUS2009258886
DESCRIPTIONUS2009264422
DESCRIPTIONUS2010004232
DESCRIPTIONUS2010022522
DESCRIPTIONUS2010029610
DESCRIPTIONUS2010048551
DESCRIPTIONUS2010152181
DESCRIPTIONUS2010152183
DESCRIPTIONUS2010160322
DESCRIPTIONUS2010160325
DESCRIPTIONUS2010184766
DESCRIPTIONUS2010190981
DESCRIPTIONUS2010197671
DESCRIPTIONUS2010286139
DESCRIPTIONUS2010298321
DESCRIPTIONUS2010298323
DESCRIPTIONUS2010298355
DESCRIPTIONUS2010305122
DESCRIPTIONUS2010317659
DESCRIPTIONUS2011059943
DESCRIPTIONUS2011082159
DESCRIPTIONUS2011086810
DESCRIPTIONUS2011124628
DESCRIPTIONUS2011177011
DESCRIPTIONUS2011223210
DESCRIPTIONUS2011224157
DESCRIPTIONUS2011224203
DESCRIPTIONUS2011288065
DESCRIPTIONUS2011318393
DESCRIPTIONUS2012059000
DESCRIPTIONUS2012071480
DESCRIPTIONUS2012077798
DESCRIPTIONUS2012077832
DESCRIPTIONUS2012108590
DESCRIPTIONUS2012128665
DESCRIPTIONUS2012129853
DESCRIPTIONUS2012142680
DESCRIPTIONUS2012157470
DESCRIPTIONUS2012157500
DESCRIPTIONUS2012184568
DESCRIPTIONUS2012190688
DESCRIPTIONUS2012196855
DESCRIPTIONUS2012277210
DESCRIPTIONUS2013029982
DESCRIPTIONUS2013029984
DESCRIPTIONUS2013053362
DESCRIPTIONUS2013065879
DESCRIPTIONUS2013072469
DESCRIPTIONUS2013090358
DESCRIPTIONUS2013109045
DESCRIPTIONUS2013131082
DESCRIPTIONUS2013165462
DESCRIPTIONUS2013172338
DESCRIPTIONUS2013184278
DESCRIPTIONUS2013225551
DESCRIPTIONUS2013225556
DESCRIPTIONUS2013245014
DESCRIPTIONUS2013253190
DESCRIPTIONUS2013253191
DESCRIPTIONUS2013253193
DESCRIPTIONUS2013267514
DESCRIPTIONUS2013267521
DESCRIPTIONUS2013267534
DESCRIPTIONUS2013296363
DESCRIPTIONUS2013338134
DESCRIPTIONUS2013344061
DESCRIPTIONUS2013345157
DESCRIPTIONUS2014005180
DESCRIPTIONUS2014005210
DESCRIPTIONUS2014010892
DESCRIPTIONUS2014011803
DESCRIPTIONUS2014018374
DESCRIPTIONUS2014024030
DESCRIPTIONUS2014045908
DESCRIPTIONUS2014051665
DESCRIPTIONUS2014073643
DESCRIPTIONUS2014079636
DESCRIPTIONUS2014088106
DESCRIPTIONUS2014094471
DESCRIPTIONUS2014094476
DESCRIPTIONUS2014094477
DESCRIPTIONUS2014113910
DESCRIPTIONUS2014155385
DESCRIPTIONUS2014155406
DESCRIPTIONUS2014330015
DESCRIPTIONUS2015005277
DESCRIPTIONUS7393848
DESCRIPTIONUS7405295
DESCRIPTIONUS7459554
DESCRIPTIONUS7514444
DESCRIPTIONUS7563787
DESCRIPTIONUS7598257
DESCRIPTIONUS7732454
DESCRIPTIONUS7825118
DESCRIPTIONUS7825148
DESCRIPTIONUS7834022
DESCRIPTIONUS7897600
DESCRIPTIONUS7932260
DESCRIPTIONUS7960396
DESCRIPTIONUS7977477
DESCRIPTIONUS8008309
DESCRIPTIONUS8088784
DESCRIPTIONUS8114870
DESCRIPTIONUS8143255
DESCRIPTIONUS8153630
DESCRIPTIONUS8153632
DESCRIPTIONUS8158616
DESCRIPTIONUS8193182
DESCRIPTIONUS8193199
DESCRIPTIONUS8202881
DESCRIPTIONUS8207153
DESCRIPTIONUS8324252
DESCRIPTIONUS8338466
DESCRIPTIONUS8349851
DESCRIPTIONUS8399442
DESCRIPTIONUS8410265
DESCRIPTIONUS8415338
DESCRIPTIONUS8420629
DESCRIPTIONUS8450335
DESCRIPTIONUS8476284
DESCRIPTIONUS8486902
DESCRIPTIONUS8486941
DESCRIPTIONUS8501751
DESCRIPTIONUS8518964
DESCRIPTIONUS8530485
DESCRIPTIONUS8541425
DESCRIPTIONUS8546399
DESCRIPTIONUS8557983
DESCRIPTIONUS8563735
DESCRIPTIONUS8569323
DESCRIPTIONUS8580794
DESCRIPTIONUS8586591
DESCRIPTIONUS8586739
DESCRIPTIONUS8586754
DESCRIPTIONUS8604043
DESCRIPTIONUS8609679
DESCRIPTIONUS8628752
DESCRIPTIONUS8673891
DESCRIPTIONUS8673933
DESCRIPTIONUS8703943
DESCRIPTIONUS8722657
DESCRIPTIONUS8722693
DESCRIPTIONWO2012020786
DESCRIPTIONWO2012020787
DESCRIPTIONWO2012030914
DESCRIPTIONWO2012135937
DESCRIPTIONWO2012135944
DESCRIPTIONWO2012155063
DESCRIPTIONWO2012158843
DESCRIPTIONWO2012162293
DESCRIPTIONWO2012162372
DESCRIPTIONWO2012162584
DESCRIPTIONWO2013006864
DESCRIPTIONWO2013010868
DESCRIPTIONWO2013010869
DESCRIPTIONWO2013028505
DESCRIPTIONWO2013067162
DESCRIPTIONWO2013067165
DESCRIPTIONWO2013074594
DESCRIPTIONWO2013081016
DESCRIPTIONWO2013170159
DESCRIPTIONWO2013170182
DESCRIPTIONWO2013173436
DESCRIPTIONWO2014028756
DESCRIPTIONWO2014173289
EXAMINATIONWO2014168975
INTERNATIONAL-SEARCH-REPORTWO2013010868
INTERNATIONAL-SEARCH-REPORTWO2015061752
OPPOSITIONWO2013010868

Non-Patent Literature (NPL) Citations (61) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BYRD ET AL., N. ENGL. J. MED., (2013), vol. 369, pages 32 - 42-
DESCRIPTION- BYRD, N. ENGL. J. MED., (2013), vol. 369, pages 32 - 42-
DESCRIPTION- CHO, CHEM. SOC. REV., (2009), vol. 38, page 443-
DESCRIPTION- CORY ET AL., TETRAHEDRON LETTERS, (1996), vol. 37, page 5675-
DESCRIPTION- DAUSSMANN ET AL., ENGINEERING IN LIFE SCIENCES, (2006), vol. 6, pages 125 - 129-
DESCRIPTION- D'CRUZ; UCKUN, ONCOTARGETS AND THERAPY, (2013), vol. 6, pages 161 - 176-
DESCRIPTION- ENGLEMAN, NAT. REV. CANCER, (2009), vol. 9, pages 550 - 562-
DESCRIPTION- HART ET AL., "Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia", BLOOD CANCER J., (2011), vol. 1, no. 11, page E44-
DESCRIPTION- HART ET AL., "SB 1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies", LEUKEMIA, (2011), vol. 25, pages 1751 - 1759-
DESCRIPTION- J. LIM ET AL., "Discovery of 1-amino- 5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase-2 (JAK2) for the treatment of myeloproliferative disorders", J. MED. CHEM., (2011), vol. 54, pages 7334 - 7349-
DESCRIPTION- KAMBOURAKIS ET AL., PHARMACHEM, (2006), vol. 5, no. 9, pages 2 - 5-
DESCRIPTION- K. GHORESCHI; A. LAURENCE; J. J. O'SHEA; JANUS KINASES, "immune cell signaling", IMMUNOL. REV., (2009), vol. 228, pages 273 - 287-
DESCRIPTION- KURT; RAY-COQUARD, ANTICANCER RES., (2012), vol. 32, pages 2463 - 70-
DESCRIPTION- MADAN ET AL., "SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis", J IMMUNOL., (2012), vol. 189, pages 4123 - 4134-
DESCRIPTION- MALACEA ET AL., COORDINATION CHEMISTRY REVIEWS, (2010), vol. 254, pages 729 - 752-
DESCRIPTION- MOORE ET AL., ACC. CHEM. RES., (2007), vol. 40, pages 1412 - 1419-
DESCRIPTION- OSSWALD ET AL., CHIMICA OGGI, (2007), vol. 25, pages 16 - 18-
DESCRIPTION- POULSEN ET AL., "Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB 1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3", J. COMPUT. AIDED MOL. DES., (2012), vol. 26, pages 437 - 450-
DESCRIPTION- SCHLUMMER ET AL., SPECIALTY CHEMICALS MAGAZINE, (2008), vol. 28, pages 48 - 49-
DESCRIPTION- SOUERS, NAT MED., (2013), vol. 19, pages 202 - 208-
DESCRIPTION- STAUFFER, CURR. TOP. MED. CHEM., (2007), vol. 7, pages 961 - 965-
DESCRIPTION- SWARTZ ET AL., CANCER RES., (2012), vol. 72, page 2473-
DESCRIPTION- "Therapeutic potential of JAK2 inhibitors", S. VERSTOVSEK, Hematology, AMERICAN SOCIETY OF HEMATOLOGY EDUCATION BOOK, (2009), pages 636 - 642-
DESCRIPTION- WILLIAM ET AL., "Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).l(8,12)]heptacosa-l(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518", J. MED. CHEM., (2011), vol. 54, pages 4638 - 4658-
DESCRIPTION- WILLIAM ET AL., "Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578", J. MED. CHEM., (2012), vol. 55, pages 2623 - 2640-
INTERNATIONAL-SEARCH-REPORT- STEPHENS DEBORAH M ET AL, "Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype", BLOOD, & 55TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; NEW ORLEANS, LA, USA; DECEMBER 07 -10, 2013, (201311), vol. 122, no. 21, page 2872, XP008177696 [A] 1-86 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- SONGDEJ NATTHAPOL ET AL, "GIST Treatment Options after Tyrosine Kinase Inhibitors", CURRENT TREATMENT OPTIONS IN ONCOLOGY MAY 2005, SPRINGER US, BOSTON, vol. 15, no. 3, doi:10.1007/S11864-014-0295-3, ISSN 1527-2729, (20140622), pages 493 - 506, (20140622), XP035381545 [A] 1 * abstract *
INTERNATIONAL-SEARCH-REPORT- GRISAFI DAVIDE ET AL, "Ibrutinib: from bench side to clinical implications", MEDICAL ONCOLOGY, SCIENCE AND TECHNOLOGY LETTERS, NORTHWOOD, GB, vol. 32, no. 9, doi:10.1007/S12032-015-0669-9, ISSN 1357-0560, (20150730), pages 1 - 10, (20150730), XP035522374 [AP] 1 * page 6; table 1 *
INTERNATIONAL-SEARCH-REPORT- QINGJIE LIU ET AL, "Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, AMSTERDAM, NL, (20150806), vol. 25, no. 19, doi:10.1016/j.bmcl.2015.07.102, ISSN 0960-894X, pages 4265 - 4269, XP055218382 [AP] 1-86 * page 4266, column 1, paragraph 2 - column 2, paragraph 2 * * page 4268, column 2, paragraph 5 *
INTERNATIONAL-SEARCH-REPORT- BRIAN J. PARK ET AL, "Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines - Lessons for design of combination targeted therapy", CANCER LETTERS, US, (20120202), vol. 320, no. 1, doi:10.1016/j.canlet.2012.01.039, ISSN 0304-3835, pages 104 - 110, XP055217954 [A] 1 * abstract *
INTERNATIONAL-SEARCH-REPORT- GIROTTI MARIA ROMINA ET AL, "No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients", MOLECULAR ONCOLOGY, ELSEVIER, AMSTERDAM, NL, (20140815), vol. 8, no. 6, doi:10.1016/J.MOLONC.2014.07.027, ISSN 1574-7891, pages 1140 - 1158, XP029054008 [AP] 1 * page 1151, column 1, paragraph 3 - column 2, paragraph 1 *
INTERNATIONAL-SEARCH-REPORT- E KLYUCHNIKOV ET AL, "Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?", BONE MARROW TRANSPLANTATION, GB, (20130527), vol. 49, no. 1, doi:10.1038/bmt.2013.72, ISSN 0268-3369, pages 1 - 7, XP055217963 [A] 1 * table 1 * * page 1, column 2, paragraph 2 *
INTERNATIONAL-SEARCH-REPORT- L. A. MATHEWS GRINER ET AL, "High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, US, (20140127), vol. 111, no. 6, doi:10.1073/pnas.1311846111, ISSN 0027-8424, pages 2349 - 2354, XP055218384 [X] 1-3,6,8,11,13,17,34-36,39,41,43,49,51,52,55,64-70,73,79-83 * abstract * * page 2352, column 1, paragraph 2 - column 2, paragraph 3 *
INTERNATIONAL-SEARCH-REPORT- IDIT SAGIV-BARFI ET AL, "Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, US, (20150217), vol. 112, no. 9, doi:10.1073/pnas.1500712112, ISSN 0027-8424, pages E966 - E972, XP055217955 [AP] 1 * page e971, column 2, paragraph 2 - paragraph 3 * * abstract *
INTERNATIONAL-SEARCH-REPORT- G. K. PHILIPS ET AL, "Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies", INTERNATIONAL IMMUNOLOGY., GB, (20141016), vol. 27, no. 1, doi:10.1093/intimm/dxu095, ISSN 0953-8178, pages 39 - 46, XP055217958 [AP] 1 * page 5, column 1, paragraph 5 *
INTERNATIONAL-SEARCH-REPORT- JENNIFER L. YORI ET AL, "Abstract LB-221: Inhibition of rapamycin-induced feedback activation of AKT with dasatinib induces complete tumor regression in a preclinical model of breast cancer.", CANCER RESEARCH, US, (20130415), vol. 73, no. 8, Suppl. 1, doi:10.1158/1538-7445.AM2013-LB-221, ISSN 0008-5472, pages LB - 221, XP055217951 [A] 1 * the whole document *
INTERNATIONAL-SEARCH-REPORT- D. CHIRON ET AL, "Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma", CANCER DISCOVERY, US, (20140731), vol. 4, no. 9, doi:10.1158/2159-8290.CD-14-0098, ISSN 2159-8274, pages 1022 - 1035, XP055218352 [A] 1-86 * abstract * * page 1031, column 1 - column 2 * * page 1032, column 2, paragraph 3 - page 1033, column 1, paragraph 2 *
INTERNATIONAL-SEARCH-REPORT- J. SCHWAMB ET AL, "B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides", BLOOD, US, (20121108), vol. 120, no. 19, doi:10.1182/blood-2012-05-431783, ISSN 0006-4971, pages 3978 - 3985, XP055218383 [X] 1-3,6,8,11,13,17,34-36,39,41,43,49,51,52,55,64-70,73,79-83 * abstract * * page 3983, column 1 * * page 3984, column 2, paragraph 1 *
INTERNATIONAL-SEARCH-REPORT- BIN CHEN ET AL, "Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells", PLOS ONE, US, (20150610), vol. 10, no. 6, doi:10.1371/journal.pone.0129663, ISSN 1932-6203, page e0129663, XP055218386 [AP] 1 * abstract * * page 5, column 3 - page 6, column 1 * * page 8, column 3 *
INTERNATIONAL-SEARCH-REPORT- VAN DEN AKKER EMILE ET AL, "The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity", BIOLOGICAL CHEMISTRY, (200405), vol. 385, no. 5, ISSN 1431-6730, pages 409 - 413, XP008177694 [A] 1 * abstract * * page 412, column 1, paragraph 3 *
INTERNATIONAL-SEARCH-REPORT- D'CRUZ OJ ET AL, "Novel Bruton's tyrosine kinase inhibitors currently in development", ONCOTARGETS AND THERAPY, GB, (20130306), vol. 6, doi:10.2147/OTT.S33732, ISSN 1178-6930, pages 161 - 176, XP055217561 [A] 1 * table 1 * * page 168, column 2 *
INTERNATIONAL-SEARCH-REPORT- ZHANG QING ET AL, "[Effect of PI3K[delta] inhibitor CAL-101 on myeloma cell lines and preliminary study of synergistic effects with other new drugs].", ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI OCT 2014, (201410), vol. 35, no. 10, ISSN 0253-2727, pages 926 - 930, XP008177739 [AP] 1 * abstract *
INTERNATIONAL-SEARCH-REPORT- HANTSCHEL O, "Targeting BCR-ABL and JAK2 in Ph+ ALL", BLOOD 20150226 AMERICAN SOCIETY OF HEMATOLOGY USA, (20150226), vol. 125, no. 9, ISSN 0006-4971, pages 1362 - 1363, XP008177695 [AP] 1-86 * the whole document *
OPPOSITION- Anonymous, "Jeko-1 CRL-3006 ™ ", ATCC - Cell Products, (20230101), ATCC - Cell Products, URL: https://www.atcc.org/products/crl-3006, (20240328), XP093146525-
OPPOSITION- Anonymous, "JVM-13 CRL-3003™", ATCC - Cell Products, (20230101), ATCC - Cell Products, URL: https://www.atcc.org/products/crl-3003, (20240328), XP093146522-
OPPOSITION- Anonymous, "Maver-1 CRL-3008 ™", ATCC - Cell Products, (20230101), ATCC - Cell Products, URL: https://www.atcc.org/products/crl-3008, (20240328), XP093146523-
OPPOSITION- Anonymous, "Mino CRL-3000 ™", ATCC - Cell Products, (20230101), ATCC - Cell Products, URL: https://www.atcc.org/products/crl-3000, (20240328), XP093146520-
OPPOSITION- Anonymous, "Obinutuzumab", Wikipedia, the free encyclopedia, (20231005), Wikipedia, the free encyclopedia, URL: https://en.wikipedia.org/w/index.php?title=Obinutuzumab&oldid=1178766560, (20240328), XP093146526-
OPPOSITION- Carsten U Niemann, "Abstract 2624: The novel Bruton's tyrosine kinase inhibitor ACP-196 shows in vivo efficacy against human chronic lymphocytic leukemia cells xenografted to the NSG mouse model | Cancer Research", Cancer Research, (2014), Cancer Research, URL: http://cancerres.aacrjournals.org/content/74/19_Supplement/2624, (20170328), XP055359423-
OPPOSITION- Chan Y Cheah, Senthil Lingaratnam, John F Seymour, "Rituximab for the treatment of follicular lymphoma", Future Oncology, (20130901), vol. 9, no. 9, pages 1283 - 1298, XP055949183-
OPPOSITION- Chisti Mohammad Muhsin, Emmanuel C Besa, "Chronic Lymphocytic Leukemia(CLL) Differential Diagnoses", Medscape, (20231207), pages 1 - 2, Medscape, URL: https://emedicine.medscape.com/article/199313-differential?form=fpf, (20240328), XP093146513-
OPPOSITION- Hoeller Sylvia; Zhou Yi; Kanagal-Shamanna Rashmi; Xu-Monette Zijun Y.; Hoehn Daniela; Bihl Michel; Swerdlow Steven H.; Rosenwald Andreas; Ott German; Said Jonathan; Dunphy Cherie H.; Bueso-Ramos Carlos E.; Lin Pei; Wang Michael; Miranda Roberto N.; Tzankov Alexander; Medeiros L. Jeffrey; Young Ken H., "Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study", Human Pathology, SAUNDERS, PHILADELPHIA, PA, US, US , (19000101), vol. 44, no. 1, doi:10.1016/j.humpath.2012.04.022, ISSN 0046-8177, pages 110 - 121, XP028960231
OPPOSITION- Davids Matthew S; Lampson Benjamin L; Tyekucheva Svitlana; Wang Zixu; Lowney Jessica C; Pazienza Samantha; Montegaard Josie; Patterson Victoria; Weinstock Matthew; Crombie Jennifer L; Ng Samuel Y; Kim Austin I; Jacobson Caron A; LaCasce Ann S; Armand Philippe; Arnason Jon E; Fisher David C; Brown Jennifer R, "Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20210914), vol. 22, no. 10, doi:10.1016/S1470-2045(21)00455-1, pages 1391 - 1402, XP086799025
OPPOSITION- M Axelrod, Z Ou, L K Brett, L Zhang, E R Lopez, A T Tamayo, V Gordon, R J Ford, M E Williams, L V Pham, M J Weber, M L Wang, "Combinatorial drug screening identifies synergistic co-targeting of Bruton’s tyrosine kinase and the proteasome in mantle cell lymphoma", Leukemia, Nature Publishing Group UK, London, London, (20140201), vol. 28, no. 2, doi:10.1038/leu.2013.249, ISSN 0887-6924, pages 407 - 410, XP055307589
OPPOSITION- Deng J; Isik E; Fernandes S M; Brown J R; Letai A; Davids M S, "Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia", Blood Cancer Journal, Nature Publishing Group UK, London, London, (20170123), vol. 31, no. 10, doi:10.1038/leu.2017.32, ISSN 0887-6924, pages 2075 - 2084, XP037653633
OPPOSITION- Kater Arnon P., Owen Carolyn, Moreno Carol, Follows George, Munir Talha, Levin Mark-David, Benjamini Ohad, Janssens Ann, Osterborg Anders, Robak Tadeusz, Simkovic Martin, Stevens Don, Voloshin Sergey, Vorobyev Vladimir, Ysebaert Loic, Qin Rui, Steele Andrew J., Schuier Natasha, Baeten Kurt, Caces Donne Bennett, Niemann Carsten U., "Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities", NEJM Evidence, (20220628), vol. 1, no. 7, doi:10.1056/EVIDoa2200006, ISSN 2766-5526, pages 1 - 13, XP093146516
OPPOSITION- C. Billard, "BH3 Mimetics: Status of the Field and New Developments", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20130901), vol. 12, no. 9, doi:10.1158/1535-7163.MCT-13-0058, ISSN 1535-7163, pages 1691 - 1700, XP055597285
OPPOSITION- Jones Jeffrey A, Byrd John C, "How will B-cell-receptor-targeted therapies change future CLL therapy?", Blood, (20140306), vol. 123, no. 10, doi:10.1182/blood-2013-, pages 1455 - 1460, XP055949190
OPPOSITION- Xiaoxian Zhao et al., "Combination of Ibrutinib With ABT-199, a BCL-2 Pathway Inhibitor: Effective Therapeutic Strategy In a Novel Mantle Cell Lymphoma Cell Line Model", Blood, (2013), vol. 122, doi:10.1182/blood.V122.21.645.645, XP086750970
OPPOSITION- Gilbert Andrew, Roughead Libby, Sansom Lloyd, "I've missed a dose; what should I do?", AUSTRALIAN PRESCRIBER, AUSTRALIAN GOVERNMENT - PUBLISHING SERVICE, CANBERRA, AU, AU , (20020201), vol. 25, no. 1, doi:10.18773/austprescr.2002.010, ISSN 0312-8008, pages 16 - 18, XP093146517
OPPOSITION- Cheah Chan Yoon, Seymour John F., "Refining the predictors of risk for central nervous system involvement in patients with mantle cell lymphoma", LEUKEMIA AND LYMPHOMA., Informa Healthcare, US, US , (20130901), vol. 54, no. 9, doi:10.3109/10428194.2013.777839, ISSN 1042-8194, pages 1859 - 1861, XP055949177

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents